Back to top
more

Alnylam Pharmaceuticals, Inc. (ALNY)

(Real Time Quote from BATS)

$132.35 USD

132.35
534,433

-0.32 (-0.24%)

Updated May 6, 2021 04:00 PM ET

After-Market: $132.54 +0.19 (0.14%) 4:18 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 13% (222 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Alnylam's (ALNY) Q1 Loss Narrower Than Expected, Revenues Beat

Alnylam (ALNY) beat estimates for both earnings and revenues in the first quarter of 2021.

Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of 2.29% and 0.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Alnylam Pharmaceuticals (ALNY) to Report a Decline in Earnings: What to Look Out for

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ironwood (IRWD) Q4 Earnings Beat on Solid Linzess Sales

Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter. However, outlook for 2021 misses market expectations.

Alnylam's (ALNY) Q4 Loss Wider Than Expected, Revenues Beat

Alnylam (ALNY) reported a wider-than-expected loss but revenues beat estimates in the fourth quarter of 2020.

Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of -8.29% and 14.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy

Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.

Alnylam (ALNY) Posts Positive Top-Line Data From Vutrisiran Study

Alnylam (ALNY) reports positive top-line results from the phase III -HELIOS-A study of vutrisiran in development for the treatment of transthyretin-mediated amyloidosis with polyneuropathy.

Novartis (NVS) Gets CRL From the FDA for Cholesterol Drug

Novartis (NVS) gets CRL from the FDA for its cholesterol drug, inclisiran, due to unresolved facility inspection-related conditions.

Why Is Alnylam (ALNY) Down 6% Since Last Earnings Report?

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alnylam (ALNY) Ends Enrollment in Advanced Hyperoxaluria Study

Alnylam (ALNY) completes enrollment in its phase III study of Oxlumo for the treatment of advanced primary hyperoxaluria type 1.

Biotech Stock Roundup: REGN's Cocktail Gets EUA, GILD & AMGN Provide Updates & More

Pipeline and regulatory updates take centerstage in the biotech sector as Regeneron (REGN) and Gilead Sciences (GILD), among others, provide updates on their pipeline candidates.

Alnylam (ALNY) Gets FDA Nod for Oxlumo to Treat Renal Disease

The FDA approves Alnylam's (ALNY) Oxlumo injection for subcutaneous use, to lower urinary oxalate levels in pediatric and adult patients with primary hyperoxaluria type 1.

Alnylam (ALNY) Gets EU Nod for Oxlumo to Treat Renal Disease

Alnylam (ALNY) gets European approval for Oxlumo (lumasiran) for the treatment of primary hyperoxaluria type 1 in all age groups.

Alnylam's (ALNY) Q3 Loss Wider Than Expected, Revenues Beat

Alnylam (ALNY) reports a wider-than-expected loss, while sales beat estimates in the third quarter of 2020.

Can Coronavirus Vaccine Efforts Aid BioNTech (BNTX) Q3 Earnings?

On BioNTech's (BNTX) upcoming Q3 earnings call, investors' focus will be on the progress and advancement of its COVID-19 vaccine candidate, currently being developed in partnership with Pfizer.

Is a Surprise Coming for Alnylam (ALNY) This Earnings Season?

Alnylam (ALNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Vaxart (VXRT) to Report Q3 Earnings: What's in the Cards?

During Vaxart's (VXRT) impending third-quarter conference call, investors will keep tabs of its progress with its oral COVID-19 vaccine candidate VXA-CoV2-1.

What Awaits AVEO Pharmaceuticals (AVEO) in Q3 Earnings?

On AVEO Pharmaceuticals' (AVEO) third-quarter earnings call, investor focus will be on the updates related to its NDA that seeks an approval for tivozanib to treat RCC in the United States.

What's in Store for Emergent (EBS) This Earnings Season?

On Emergent's (EBS) upcoming third-quarter earnings call, investors will focus on the company's recent CDMO collaborations to help partners manufacture a vaccine against COVID-19.

What's in Store for AstraZeneca (AZN) This Earnings Season?

AstraZeneca's (AZN) third-quarter results are expected to reflect the impact of new drug sales.

Kinjel Shah headshot

5 Drug/Biotech Stocks Set to Outpace Q3 Earnings Estimates

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Solid Biosciences (SLDB) to PostQ3 Earnings: What's in Store?

Solid Biosciences (SLDB) will provide updates on its lead pipeline candidate,SGT-001, along with others when it releases third-quarter 2020 results.

Can Coronavirus Vaccine Efforts Aid Novavax (NVAX) Q3 Earnings?

During Novavax's (NVAX) upcoming third-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.